Nayla Mumneh
Novartis (United States)(US)Tris Pharma (United States)(US)Hanover College(US)
Publications by Year
Research Areas
Neurogenetic and Muscular Disorders Research, Asthma and respiratory diseases, Coagulation, Bradykinin, Polyphosphates, and Angioedema, Allergic Rhinitis and Sensitization, Hemophilia Treatment and Research
Most-Cited Works
- → Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial(2021)539 cited
- → Safety and Usage of C1-Inhibitor in Hereditary Angioedema: Berinert Registry Data(2016)59 cited
- → Omalizumab in Asthma with Fixed Airway Obstruction: Post Hoc Analysis of EXTRA(2021)25 cited
- → Fixed-Dose Subcutaneous C1-Inhibitor Liquid for Prophylactic Treatment of C1-INH-HAE: SAHARA Randomized Study(2019)15 cited
- → Angioedema with severe acute abdominal pain: Think of hereditary angioedema(2021)10 cited
- → Outcomes for patients in the RESTORE registry with spinal muscular atrophy and four or more SMN2 gene copies treated with onasemnogene abeparvovec(2024)7 cited
- → Pregnancy and infant outcomes among pregnant women with Chronic Spontaneous Urticaria (CSU) treated with omalizumab: a descriptive analysis from the EXPECT pregnancy registry(2021)2 cited
- → Safety and tolerability of onasemnogene abeparvovec for patients with spinal muscular atrophy weighing ≤17 kg and ≤24 months old from OFELIA, a phase 4, open-label, multicenter, non-randomised, interventional study(2025)2 cited
- → 161P Long-term safety of onasemnogene abeparvovec for patients with spinal muscular atrophy: real-world findings from the RESTORE Registry(2024)1 cited
- → The Zolgensma Journey: A Groundbreaking Therapy for SMA(2024)1 cited